Loading…
Back To Schedule
Wednesday, June 17 • 8:00am - 9:00am
#304 L: Strategic Directions from Global Medicines Regulators: The ICMRA Statement on Combatting Antimicrobial Resistance

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-20-586-L04-P; CME 1.00; IACET 1.00; RN 1.00

The ICMRA recognizes that antimicrobial resistance (AMR) is a complex, global and multi-faceted problem which poses unique challenges and is committing, in collaboration with WHO, to coordinate regulators efforts around the globe for the fight against AMR.

Learning Objectives

Analyze the challenges faced by global regulators for development, commercialization and viability of products that tackle antimicrobial resistance (AMR) and formulate solutions; Recognize the role of the International Coalition of Medicines Regulatory Authorities (ICMRA) in providing strategic directions and coordination to global medicines regulators.

Chair

Agnès Saint-Raymond, DrMed

Speaker

Health Canada Update
Pierre Sabourin, MBA

Panelist
Guido Rasi, MD

Panelist
John Farley, MD, MPH

Panelist
Sini Eskola, MPharm, MSc


Speakers
avatar for Agnès Saint-Raymond

Agnès Saint-Raymond

Head of Division International Affairs, European Medicines Agency, Netherlands
Agnes is an MD and qualified French Paediatrician. She worked as a paediatrician in a paediatric Hospital in Paris, France, then in pharmaceutical industry, and then moved to the French Medicines Agency. In 2000 she joined the European Medicines Agency (EMA) and was responsible for... Read More →
avatar for Sini Eskola

Sini Eskola

Director Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations (EFPIA)
Sini is working as Regulatory, Drug Development and Manufacturing Director at EFPIA since 2014 and leads the team since 2018. She is responsible for various regulatory policy and advocacy activities in relation to regulatory science and regulatory strategy. She has previously worked... Read More →
JF

John Farley

Director, Office of Infectious Diseases, OND, CDER, FDA, United States
Dr. John Farley is presently Director of the Office of Infectious Diseases in the Office of New Drugs at CDER, FDA. His office is responsible for the review of new antiviral and antibacterial drugs. In addition to new drug review work, Dr. Farley’s work at FDA has included implementation... Read More →
avatar for Guido Rasi

Guido Rasi

Executive Director, European Medicines Agency
Prof Guido Rasi began his second term as Executive Director of EMA on 16 November 2015. From November 2014 to mid-November 2015, he served as EMA’s Principal Adviser in Charge of Strategy. From November 2011 to November 2014 he was the Executive Director of the EMA and a member... Read More →
avatar for Pierre Sabourin

Pierre Sabourin

Assistant Deputy Minister, Health Products and Food Branch, Health Canada, Canada
Pierre Sabourin was appointed Assistant Deputy Minister (ADM) of the Health Products and Food Branch (HPFB) at Health Canada in 2016. The branch plays a vital role in protecting and promoting the health and safety of all Canadians by excelling as a trusted scientific and regulatory... Read More →

Wednesday June 17, 2020 8:00am - 9:00am EDT
TBD Virtual Event Horsham, PA 19044
  09: Regulatory, Session